KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin (2016 - 2025)

TherapeuticsMD's EBITDA Margin history spans 16 years, with the latest figure at 173.8% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 7605.0% year-over-year to 173.8%; the TTM value through Dec 2025 reached 131.7%, up 19294.0%, while the annual FY2025 figure was 145.27%, 20181.0% up from the prior year.
  • EBITDA Margin reached 173.8% in Q4 2025 per TXMD's latest filing, down from 109.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 32264.66% in Q2 2022 to a low of 8182.2% in Q3 2022.
  • Average EBITDA Margin over 5 years is 296.69%, with a median of 202.78% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: surged 3245009bps in 2022, then crashed -3281706bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 230.0% in 2021, then soared by 149bps to 113.32% in 2022, then crashed by -255bps to 175.9% in 2023, then surged by 44bps to 97.75% in 2024, then crashed by -78bps to 173.8% in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EBITDA Margin are 173.8% (Q4 2025), 109.95% (Q3 2025), and 73.0% (Q2 2025).